Genentech, a member of the Roche Group, announced today plans to invest more than $700 million in a new 700,000 square foot state-of-the-art drug manufacturing facility in Holly Springs, NC.

基因泰克（罗氏集团成员）今天宣布计划投资超过 7 亿美元，在北卡罗来纳州霍利斯普林斯建设一座占地 70 万平方英尺的最先进的药物生产设施。

The project will add more than 400 high-wage manufacturing jobs when the site is operational and more than 1,500 construction jobs during site development. The new facility will ultimately support Roche and Genentech’s future portfolio of next-generation obesity medicines and this initial investment could expand in the future based on business needs and the U.S.

该项目在场地投入运营后将增加400多个高薪制造业岗位，在场地开发期间将创造1500多个建筑业岗位。新工厂最终将支持罗氏和基因泰克未来下一代肥胖症药物的产品组合，根据业务需求和美国的需要，这项初步投资未来可能会扩大。

policy environment. .

政策环境。

Roche and Genentech’s current U.S. footprint includes 13 manufacturing and 15 R&D sites across the company’s Pharmaceutical and Diagnostics Divisions and 25,000 employees in 24 sites across eight U.S. states.

罗氏和基因泰克目前在美国的布局包括13个生产场地和15个研发基地，分布在公司的制药和诊断部门，以及在8个州24个地点的25,000名员工。

Genentech CEO Ashley Magargee:

基因泰克首席执行官阿什利·马加吉：

“Our new facility near Raleigh, North Carolina, an established biopharmaceutical talent hub, will serve as an important new setting within our manufacturing network to help deliver on the promise of our company’s life-changing science and industry-leading pipeline. We are thrilled to establish this relationship with the city of Holly Springs, where we expect to have a positive impact on the local economy and community, as we have across the United States since we pioneered the biotech industry nearly 50 years ago.”.

“我们位于北卡罗来纳州罗利附近的新工厂，作为一个成熟的生物制药人才中心，将成为我们制造网络中一个重要的新场所，有助于实现我们公司改变生命的科学和行业领先的产品线的承诺。我们很高兴与霍利斯普林斯市建立这种关系，我们预计这将对当地经济和社区产生积极影响，正如我们在近50年前开创生物技术行业以来，在美国各地所做的那样。”

Josh Stein, Governor of North Carolina:

北卡罗来纳州州长乔什·斯坦：

“I’m proud that Genentech has chosen North Carolina for its first facility on the East Coast. This major investment in Holly Springs shows that our state continues to be a leading destination for life sciences and advanced manufacturing. With more than 400 new jobs on the way, this project will strengthen our economy, create opportunities for our people, and advance cutting-edge scientific innovation right here in North Carolina.”.

“我很自豪基因泰克选择了北卡罗来纳州作为其在东海岸的第一个设施。这项对霍利斯普林斯的重大投资表明，我们的州仍然是生命科学和先进制造业的领先目的地。随着400多个新工作岗位的到来，这个项目将增强我们的经济实力，为我们的人民创造机会，并在北卡罗来纳州推动前沿的科学创新。”

Together, Roche and Genentech are advocating for a vibrant biotech community and investing in the infrastructure, talent, and technologies needed to deliver the next generation of medical breakthroughs. These efforts are designed to help scale biotech innovation faster, and to ensure that the U.S. remains a leader in discovering, developing and manufacturing life-changing medicines for years to come. .

罗氏和基因泰克共同致力于打造一个充满活力的生物技术社区，投资于基础设施、人才和技术，以实现下一代医学突破。这些努力旨在帮助加快生物技术创新的规模化，确保美国在未来多年内仍然是发现、开发和生产改变生命药物的领导者。

About Genentech

关于基因泰克公司

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

成立于40多年前的基因泰克是一家领先的生物技术公司，致力于发现、开发、制造和销售用于治疗患有严重和危及生命的疾病的药物。该公司是罗氏集团的成员，总部位于加利福尼亚州南旧金山。

For additional information about the company, please visit http://www.gene.com. .

有关公司的更多信息，请访问 http://www.gene.com。

About Roche

关于罗氏

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world.

罗氏于1896年在瑞士巴塞尔成立，是最早生产品牌药物的工业制造商之一，现已发展成为全球最大的生物技术公司和体外诊断领域的全球领导者。该公司追求科学卓越，致力于发现和开发药物及诊断工具，以改善和拯救世界各地人们的生命。

We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice..

我们是个性化医疗的先驱，希望进一步改变医疗服务的提供方式，以产生更大的影响。为了给每个人提供最好的护理，我们与许多利益相关者合作，将我们在诊断和制药领域的优势与临床实践中的数据洞察相结合。

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045..

超过125年以来，可持续发展一直是罗氏业务的重要组成部分。作为一家以科学为驱动的公司，我们对社会的最大贡献在于开发创新药物和诊断工具，帮助人们过上更健康的生活。罗氏致力于科学基础目标倡议和可持续市场倡议，到2045年实现净零排放。

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

基因泰克（Genentech）是罗氏集团在美国的全资子公司。罗氏是日本中外制药公司的最大股东。

For more information, please visit http://www.roche.com.

有关更多信息，请访问 http://www.roche.com。

All trademarks used or mentioned in this release are protected by law.

本发布中使用或提到的所有商标均受法律保护。

Additional Quote for Media Use:

媒体使用的附加引语：

U.S. Senator Thom Tillis, North Carolina

美国参议员汤姆·蒂利斯，北卡罗来纳州

“Genentech's investment in North Carolina marks a significant milestone for our state's biotechnology sector. I congratulate Genentech on their commitment to fostering innovation and creating high-quality jobs for our residents.”

“基因泰克在北卡罗来纳州的投资标志着我们州生物技术领域的一个重要里程碑。我祝贺基因泰克致力于推动创新并为我们的居民创造高质量的就业机会。”

Source: gene.com

来源：gene.com